The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
This is the sight that greeted one environmental conservationist - a deer with its head stuck in a light globe.
A serial killer dubbed the "Grim Sleeper" could face the death penalty after being convicted of murdering nine women and a teenage girl.
Britons must have e-passports to visit America or risk being turned away, travellers have been warned.